Whitehawk Therapeutics, Inc.
US ˙ NasdaqCM ˙ US00032Q1040

Introduction

This page provides a comprehensive analysis of the known insider trading history of Bryan Ball. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Bryan Ball has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:AADI / Aadi Bioscience, Inc. See remarks 202,853
US:ICPT / Intercept Pharmaceuticals Inc Chief Qual. Officer & SVP Ops. 25,178
US:US452907AK45 / Immunomedics, Inc. Bond 4.750% 2/1 Chief Quality Officer 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Bryan Ball. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases WHWK / Whitehawk Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in WHWK / Whitehawk Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

WHWK / Whitehawk Therapeutics, Inc. Insider Trades
Insider Sales WHWK / Whitehawk Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in WHWK / Whitehawk Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-03-03 AADI BALL BRYAN 2,147 2.3500 2,147 2.3500 5,045 7 1.9300 -901 -17.87

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

WHWK / Whitehawk Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Bryan Ball as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-03-04 2025-03-04 4 AADI Aadi Bioscience, Inc.
Common Stock
A - Award 100,000 202,853 97.23 2.40 240,000 486,847
2025-03-04 2025-03-03 4 AADI Aadi Bioscience, Inc.
Common Stock
S - Sale -2,147 102,853 -2.04 2.35 -5,045 241,705
2025-03-04 2025-03-01 4 AADI Aadi Bioscience, Inc.
Common Stock
M - Exercise 5,000 105,000 5.00
2024-04-26 3 AADI Aadi Bioscience, Inc.
Common Stock
100,000
2022-07-13 2022-07-11 4 ICPT INTERCEPT PHARMACEUTICALS, INC.
Common Stock
F - Taxes -436 25,178 -1.70 14.57 -6,353 366,843
2022-04-13 2022-04-11 4 ICPT INTERCEPT PHARMACEUTICALS, INC.
Common Stock
F - Taxes -531 25,614 -2.03 17.19 -9,128 440,305
2022-01-31 2022-01-27 4 ICPT INTERCEPT PHARMACEUTICALS, INC.
Option to Purchase Common Stock
A - Award 6,100 6,100
2022-01-31 2022-01-27 4 ICPT INTERCEPT PHARMACEUTICALS, INC.
Common Stock
A - Award 3,600 26,145 15.97
2022-01-13 2022-01-11 4 ICPT INTERCEPT PHARMACEUTICALS, INC.
Common Stock
F - Taxes -2,455 22,545 -9.82 16.83 -41,318 379,432
2021-01-11 2021-01-11 4 ICPT INTERCEPT PHARMACEUTICALS, INC.
Option to Purchase Common Stock
A - Award 39,185 39,185
2021-01-11 2021-01-11 4 ICPT INTERCEPT PHARMACEUTICALS, INC.
Common Stock
A - Award 25,000 25,000
2020-10-23 2020-10-23 4 IMMU IMMUNOMEDICS INC
Stock Option (Right to Buy)
D - Sale to Issuer -261,937 0 -100.00
2020-10-23 2020-10-23 4 IMMU IMMUNOMEDICS INC
Common Stock
D - Sale to Issuer -10,000 0 -100.00
2020-03-05 2020-03-04 4 IMMU IMMUNOMEDICS INC
Stock Option (right to buy)
A - Award 51,600 51,600
2019-10-03 2019-10-03 4 IMMU IMMUNOMEDICS INC
Common Stock, $0.01 par value per share
P - Purchase 5,000 10,000 100.00 14.18 70,896 141,793
2019-09-10 2019-09-10 4 IMMU IMMUNOMEDICS INC
Stock Option (right to buy)
A - Award 10,440 10,440
2019-09-10 2019-09-06 4 IMMU IMMUNOMEDICS INC
Stock Option (right to buy)
A - Award 57,040 57,040
2019-06-21 2019-06-20 4 IMMU IMMUNOMEDICS INC
Common Stock, $0.01 par value per share
P - Purchase 5,000 5,000 13.35 66,750 66,750
2019-03-07 2019-03-05 4 IMMU IMMUNOMEDICS INC
Stock Option (right to buy)
A - Award 142,857 142,857
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)